SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
PolyMedix
An SI Board Since April 2010
Posts SubjectMarks Bans Symbol
77 5 0 PYMX
Emcee:  tnsaf Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
27Worrisome side effects occurred days 9 to 13. This drug is designed to be takenmcbio-2/26/2011
26Is it just me or are the side effects seen in this a trial a little worrisome? tuck-2/26/2011
25PolyMedix Successfully Completes Phase 1 Exposure Escalation Safety Study With Ptnsaf-2/25/2011
24PolyMedix Initiates Phase 2 Clinical Trial with Novel Heptagonist, PMX-60056 9 Ftnsaf-2/14/2011
23PolyMedix to Present at the 13th Annual BIO CEO Conference BIO CEO & Investtnsaf-2/7/2011
22There has been an interesting discussion at IH about bacterial resistance to deftnsaf11/22/2011
21According to yahoo: Rodman & Renshaw initiates PYMX with a Market OutperformDaveAu-12/22/2010
20PolyMedix Expands Research Science Advisory Board <i>[The SAB list isn'tnsaf-11/24/2010
19PolyMedix and University of Massachusetts Receive $750,000 Contract from U.S. Artnsaf-11/20/2010
18Competition from Portola Pharmaceuticals From a post by DewDiligence on IH: siltnsaf-11/16/2010
17PolyMedix Obtains Regulatory Clearance for its United States IND Application fortnsaf-11/11/2010
16Clinical Trial information for Phase 2 trial of PMX-30063 <i> Initial Treatnsaf-10/25/2010
15PolyMedix Provides Updates on PMX-60056 Heptagonist Program Planning Phase 2 Cltnsaf-10/22/2010
14PolyMedix to Present at the BioCentury NewsMakers in the Biotech Industry Confertnsaf-10/20/2010
13PolyMedix Initiates Phase 2 Clinical Trial with Novel Antibiotic, PMX-30063 Newtnsaf-9/28/2010
12PolyMedix to Present at the Rodman & Renshaw Global Investment Conference Rtnsaf-9/11/2010
11PolyMedix to Present Antibiotic Data at the 50th Interscience Conference on Antitnsaf-9/8/2010
10PolyMedix Successfully Completes Phase 1B/2 Heparin Dose-Ranging Study with PMX-tnsaf-8/17/2010
9PolyMedix Receives NIH Grant to Develop New Antimicrobials for the Treatment of tnsaf-7/7/2010
8>> The small molecules should be cheaper to make and maybe more effective scaram(o)uche-6/8/2010
7Hi, Rick. XOMA's approach with Neuprex was to modify a piece of a natural ptnsaf-6/7/2010
6Hey, Jason.... thanks for the thread! I guess one first question might be....scaram(o)uche-6/4/2010
5PolyMedix Receives National Science Foundation Grant to Support Development of Atnsaf-6/4/2010
4PolyMedix Successfully Completes Phase 1B Clinical Study to Reverse Low Moleculatnsaf-6/3/2010
3<i>Notes from Rodman & Renshaw Healthcare Conference May 17</i> tnsaf-6/2/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News